DEA Moves to Temporarily Schedule Synthetic 7-OH Opioid Compounds Amid Rising Public Health Concerns
The U.S. Drug Enforcement Administration (DEA) has announced plans to temporarily classify 7-hydroxymitragynine (7-OH) and three closely related synthetic substances as Schedule I controlled substances under the Controlled Substances Act (CSA). The move comes after the U.S. Department of Health and Human Services (HHS) concluded that these compounds have no currently accepted medical use and a high potential for abuse, paving the way for stricter federal regulation.
The proposed scheduling is aimed specifically at highly concentrated and synthetic forms of 7-OH, which federal officials say have become increasingly common in commercial products and present a growing threat to public health and safety.
Two Federal Notices Issued
On July 1, 2026, the DEA submitted two separate Notices of Intent (NOIs) to the Federal Register.
The first notice addresses products containing 7-hydroxymitragynine above a specified concentration threshold, while the second covers three structurally related synthetic compounds:
- Mitragynine pseudoindoxyl (MP)
- MGM-15
- MGM-16
Once the temporary scheduling becomes effective, the manufacture, distribution, sale, importation, and possession of these substances will become subject to the criminal, civil, and administrative penalties established under the Controlled Substances Act.
The temporary scheduling gives federal and state law enforcement agencies additional authority to regulate these compounds while permanent scheduling is evaluated.
Federal Officials Cite Growing Safety Risks
DEA Administrator Terrance Cole said the agency's action is intended to address the rapid growth of synthetic opioid-like products that are increasingly being sold throughout the United States.
According to Cole, today's marketplace contains a growing number of highly concentrated synthetic 7-OH products that differ significantly from naturally occurring kratom. He stated that temporary scheduling provides law enforcement and public health officials with important tools to reduce the availability of substances believed to pose serious health risks.
Cole also emphasized the DEA's continued collaboration with the Food and Drug Administration (FDA) and the Department of Health and Human Services to respond quickly when new synthetic drugs emerge.
HHS Secretary Robert F. Kennedy Jr. supported the decision, stating that the department's scientific review concluded these substances carry significant abuse potential and contribute to addiction risks. He noted that the federal government intends to continue taking action against synthetic opioid products that threaten public health while pursuing enforcement against manufacturers and distributors of deceptive or dangerous products.
Understanding 7-Hydroxymitragynine
7-Hydroxymitragynine, commonly abbreviated as 7-OH, is a naturally occurring alkaloid found in very small amounts within the leaves of Mitragyna speciosa, more commonly known as kratom.
Native to Southeast Asia, kratom has traditionally been used for centuries in certain cultural and ceremonial settings. The plant contains dozens of naturally occurring alkaloids, with mitragynine being the most abundant and 7-OH occurring only in trace concentrations.
Although naturally present in kratom, 7-OH has opioid-like activity and interacts with opioid receptors in the brain. Scientific studies have shown it is considerably more potent than mitragynine, making it a particular focus for regulators when concentrated or synthesized outside of the plant.
Synthetic Products Are Driving Concern
Federal agencies stress that the current action does not target traditional botanical kratom products that contain naturally occurring levels of 7-OH below the specified threshold.
Instead, the DEA is focusing on synthetically manufactured or chemically concentrated products that contain substantially elevated levels of the compound.
Officials say these products are often marketed as legal alternatives while producing much stronger and less predictable opioid-like effects than naturally occurring kratom.
Because of their potency and inconsistent manufacturing practices, authorities believe these concentrated products may significantly increase the risk of misuse, dependence, overdose, and other serious adverse health outcomes.
Rapid Growth in Commercial Availability
The DEA reports that products containing synthetic or semi-synthetic 7-OH have become increasingly accessible across the United States.
Consumers can now find these products through numerous retail channels, including:
- Gas stations
- Convenience stores
- Smoke shops
- Vape stores
- Online retailers
They are sold in multiple forms, including:
- Gummies
- Tablets
- Capsules
- Powders
- Dissolvable oral strips
Laboratory testing conducted by the DEA has found that many commercial products contain far higher concentrations of 7-OH than those naturally present in kratom leaves, raising concerns about inconsistent dosing and increased toxicity.
Officials warn that consumers may not realize these products contain synthetic ingredients or unusually high concentrations of psychoactive compounds.
Part of a Broader Strategy Against Synthetic Opioids
The temporary scheduling effort forms part of the federal government's broader strategy to address the ongoing opioid crisis by responding more quickly to newly emerging synthetic substances.
While overdose deaths have declined in recent years, public health agencies continue to warn that new synthetic opioids and opioid-like compounds are entering the illicit and commercial markets, often outpacing existing regulations.
Federal officials believe proactive scheduling actions can help limit the spread of these substances before they become more deeply established within the drug supply.
What Happens Next?
Following publication in the Federal Register, the DEA's temporary scheduling order will take effect according to the timeline outlined in the Controlled Substances Act.
Once active, covered forms of 7-OH, mitragynine pseudoindoxyl, MGM-15, and MGM-16 will be treated as Schedule I controlled substances, placing them in the same regulatory category as other drugs considered to have a high abuse potential and no accepted medical use under federal law.
The action does not prohibit traditional botanical kratom products that contain only naturally occurring trace levels of 7-OH below the established threshold. Instead, it specifically targets synthetic and highly concentrated formulations that federal agencies believe present an imminent risk to public health.
As research into kratom-derived compounds continues, regulators are expected to closely monitor emerging evidence while balancing public safety, scientific investigation, and future therapeutic development.
Source: DEA